The use of oral lacosamide in a patient with refractory partial epileptic status;Uso de lacosamida oral en un paciente con estado epiléptico parcial refractario

Revista de Neurologia

Volumn 50, Issue 10, 2010, Pages 603-606

  Turpín Fenoll, Laura ^a   Millán Pascual, Jorge ^a   Navarro Muñoz, Santiago ^a   Del Saz Saucedo, Pablo ^a   Rueda Medina, Ignacio ^a  

^a Servicio de Aparato Digestivo   (Spain)

Author keywords

Crisis; Epilepsy; Lacosamide; Non convulsive status; Oral; Treatment

Indexed keywords

ANTICOAGULANT AGENT; CLOBAZAM; ETIRACETAM; HARKOSERIDE; OXCARBAZEPINE; VALPROIC ACID;

AGED; ARTICLE; BRADYCARDIA; BRAIN ISCHEMIA; CASE REPORT; DRUG DOSE REDUCTION; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; HUMAN; HYPOXIA; MALE; RESUSCITATION; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

EID: 77953045385     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5010.2010281     Document Type: Article

References (24)

1. Shorvon S, Baulac M, Cross H, Trinka E, Walker M. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 2008; 49: 1277-1285
2. Kälviäinen R. Status epilepticus treatment guidelines. Epilepsia 2007; 48 (Suppl 8): S99-102.
3. Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P et al. EFNS guidelines on the management of status epilepticus in adults. Eur J Neurol 2010; 17: 348-355
4. Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003; 61: 1066-1073
5. Jordan KG, Hirsch J. In nonconvulsive status epilepticus (CSE), treat to burst-suppression: pro and con. Epilepsia 2006; 47 (Suppl 1): S41-5.
6. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319
7. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Thomson T. New antiepileptic drugs: currently in clinics. Progress report on new antiepileptic drugs: a summary of the Eight EILAT Conference (EILAT VIII). Epilepsy Res 2007; 73: 1-52.
8. Marín-Muñoz H, Gil-Nagel A, Thomas D, Scharfenecker U, Nickel B, Doty P, et al. La lacosamida tiene un bajo potencial de interacciones farmacológicas [abstract P19]. VII Reunión Anual de la Asociación Madrileña de Neurología. Rev Neurol 2010; 50: 504.
9. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status after epilepticus failure of first-line therapy. Epilepsy Behav 2009; 14: 429-431
10. Tilz C, Resch R, Hofer T, Eggers C. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia 2010; 51: 316-317
11. Litt B, Wityk RJ, Hertz SH, Mullen PD, Weiss H, Ryan DD et al. Intravenous levetiracetam in treatment of benzodiacepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008; 79: 588-589
12. Vespa P. Continuous EEG monitoring for detection of seizures in traumatic brain injury, infarction, and intracerebral hemorrhage: 'to detect and protect'. J Clin Neurophysiol 2005; 22: 99-106.
13. Waterhouse EJ, Vaughan JK, Barnes TY, Boggs JG, Towne AR, Kopec L et al. Synergistic effect of status epilepticus and ischemic brain injury on mortality. Epilepsy Res 1998; 29: 175-183
14. Mercadé-Cerdá J, Sánchez-Álvarez JC. Crisis epilépticas y estado epiléptico. Recomendaciones para el diagnóstico y tratamiento de las crisis epilépticas y de la epilepsia en situaciones de urgencia. Barcelona: Viguera; 2008.
15. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13: 21-42.
16. Brandt Heile A, Potschka H, Stoehr T, Löscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006; 47: 1803-1809 (Pubitemid 44730049)
17. Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Neuropharmacology 2006; 50: 1016-1029
18. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308-1317 (Pubitemid 47063096)
19. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443-453
20. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; Jan 27. [Epub ahead of print].
21. Cross SA, Curran MP. Lacosamide in partial-onset seizure. Drugs 2009; 69: 449-459
22. Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49: 418-424 (Pubitemid 351294527)
23. Wehner T, Bauer S, Hamer HM, Hattemer K, Immisch I, Knake S, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009; 16: 423-425
24. Stöhr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, et al. Lacosamide, a novel anticonvulsivant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007; 74: 147-154